This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 26.67% and 79.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of 6.76% and 12.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -425% and 98.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0% and 48.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 8.33% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -122.58% and 2.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -333.33% and 96.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?
by Zacks Equity Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Clearside Biomedical, Inc. (CLSD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 244.44% and 95.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -88.89% and 8.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 11.11% and -7.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Clearside Biomedical, Inc. (CLSD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 8.33% and 5.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Clearside Biomedical, Inc. (CLSD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Clearside Biomedical (CLSD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.
Analysts Estimate Clearside Biomedical, Inc. (CLSD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.69% and -98.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) NGS-Based Platform Approved for Use in Russia
by Zacks Equity Research
Illumina and R-Pharm's in-vitro diagnostics platform registration will drive the expansion of Next Generation Sequencing-based clinical diagnostics across Russia.
QIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing
by Zacks Equity Research
QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.
Earnings Preview: Clearside Biomedical, Inc. (CLSD) Q4 Earnings Expected to Decline
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.